首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

2028270

乙肝疫苗市場規模、佔有率、成長率及全球產業分析：按類型、應用和地區分類，預測2026-2034年

Hepatitis B Vaccine Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034

出版日期: 2026年03月30日 | 出版商:

Fortune Business Insights Pvt. Ltd. | 英文 126 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

乙肝疫苗市場成長要素

由於感染率上升、政府擴大免疫接種計畫以及聯合疫苗研發投入的增加，全球乙肝疫苗市場持續穩定成長。產業預測，2025年市場規模將達到93.4億美元，2026年達到98.7億美元，到2034年將進一步成長至155.4億美元，2026年至2034年的複合年成長率（CAGR）為5.83%。

市場規模與價值概覽

乙肝疫苗市場成長的主要驅動力是乙肝病毒（HBV）感染造成的全球疾病負擔。根據世界衛生組織（WHO）統計，2019年全球約有2.96億人患有慢性B肝，預計每年新增感染病例約150萬例（2023年預測）。如此沉重的疾病負擔持續推動全球對免疫接種計劃的需求。

2025年，北美以31.2億美元的市場規模引領全球市場，佔全球市佔率的33.38%。由於健全的醫療衛生基礎設施、先進疫苗的早期部署以及政府主導的乙型肝炎根除策略，該地區預計到2026年市場規模將達到32.7億美元。

區域趨勢

北美地區憑藉著較高的公眾意識、強勁的疫苗接種率和積極主動的公共衛生政策，仍然是重要的區域市場。在美國，透過FDA的快速核准和新型聯合疫苗的推出，疫苗的可近性持續擴大。

亞太地區是第二大市場，預計到 2025 年將達到 30.5 億美元，到 2026 年將達到 32.4 億美元。由於人口密度高、乙型肝炎患病率上升以及中國和印度等國家擴大免疫接種計劃，該地區預計將經歷最快的成長。

預計到2025年，歐洲的疫苗市場規模將達到20.2億美元，到2026年將達到21.4億美元，主要得益於50多個國家較高的新生兒疫苗接種率。同時，由於公眾意識的提高和政府主導的疫苗宣傳活動運動，世界其他地區（拉丁美洲、中東和非洲）的疫苗市場規模也逐漸擴大。

市場促進因素

乙型肝炎病毒感染在全球日益流行是推動疫苗接種率上升的成長要素之一。乙型肝炎病毒（HBV）可導致嚴重的肝臟疾病，如肝硬化和肝細胞癌。感染途徑包括血液傳播和母嬰傳播，因此新生兒疫苗接種至關重要。

政府主導的根除計畫也顯著促進了市場成長。例如，在歐洲和世界衛生組織的支持下，嬰兒疫苗接種率提高，孕婦篩檢加大，降低了多個地區的感染率。

另一個重要因素是聯合疫苗的日益普及，聯合疫苗可以預防多種疾病，提高疫苗接種效率和病患依從性。

行業趨勢和主要公司

乙肝疫苗市場競爭非常激烈，主要參與者都專注於創新、合作和擴大生產能力。

主要公司包括：

賽諾菲持續在全球擴大其疫苗生產基礎設施，並大力投資先進的生產技術。
葛蘭素史克公司積極參與乙型肝炎疫苗的分發和全球免疫計畫。
默克公司為聯合疫苗的研發和全球供應做出了貢獻。
Dynavax Technologies 公司以其重組乙型肝炎疫苗 HEPLISAV-B 而聞名。
VBI Vaccines Inc. 專注於創新多抗原乙肝疫苗，例如 PreHevbrio。
吉利德科學公司致力於研究治療方法和聯合治療策略。
包括中國生物技術有限公司（SINOVAC）在內的中國製造商和其他生物技術公司正在擴大產能，以滿足不斷成長的國內外需求。

市場區隔趨勢

按類型分類，預計到2026年，聯合疫苗將佔市場主導地位，市佔率達61.18%，這主要得益於其更高的免疫抗原性、成本效益和更廣泛的疾病預防效果。單價疫苗的需求依然強勁，尤其是在兒童免疫接種計畫中。

就分銷管道而言，由於新生兒疫苗通常在醫療機構接種，預計到 2026 年，醫院和零售藥局將佔最大佔有率，達到 64.69%。政府供應商也發揮著重要作用，在國家免疫規劃和全球衛生舉措的推動下，預計將佔約 65% 的佔有率。

The global hepatitis B vaccine market is experiencing steady expansion due to rising infection prevalence, increasing government immunization programs, and strong R&D investments in combination vaccine development. According to industry estimates, the market was valued at USD 9.34 billion in 2025 and is projected to reach USD 9.87 billion in 2026, further expanding to USD 15.54 billion by 2034, registering a CAGR of 5.83% during 2026-2034.

Market Size and Value Overview

The growth of the hepatitis B vaccine market is primarily driven by the global burden of hepatitis B virus (HBV) infections. According to the World Health Organization (WHO), around 296 million people were living with chronic hepatitis B in 2019, with approximately 1.5 million new infections annually (2023 estimate). This significant disease burden continues to create sustained demand for preventive vaccination programs worldwide.

In 2025, North America dominated the global market with a value of USD 3.12 billion, accounting for 33.38% of total market share. The region is projected to reach USD 3.27 billion in 2026, supported by strong healthcare infrastructure, early adoption of advanced vaccines, and government-led hepatitis elimination strategies.

Regional Insights

North America remains the leading regional market due to high awareness, strong vaccination coverage, and active public health policies. The United States continues to expand vaccination access through FDA fast-track approvals and new combination vaccine introductions.

Asia Pacific is the second-largest market, valued at USD 3.05 billion in 2025, and projected to reach USD 3.24 billion in 2026. This region is expected to witness the fastest growth due to high population density, rising HBV prevalence, and expanding immunization programs in countries such as China and India.

Europe accounted for USD 2.02 billion in 2025 and is expected to reach USD 2.14 billion in 2026, driven by strong newborn vaccination coverage across more than 50 countries. Meanwhile, the Rest of the World (Latin America and Middle East & Africa) is gradually expanding due to increasing awareness and government-led vaccination campaigns.

Market Drivers

A major growth driver is the increasing prevalence of hepatitis B infection globally. HBV is responsible for severe liver diseases such as cirrhosis and hepatocellular carcinoma. Transmission occurs through infected blood and maternal-to-child transmission, making newborn vaccination critical.

Government-led elimination programs are also significantly boosting market growth. For example, European and WHO-supported initiatives have achieved high infant vaccination coverage and improved screening of pregnant women, reducing infection rates in several regions.

Another key driver is the increasing adoption of combination vaccines, which provide protection against multiple diseases, improving immunization efficiency and patient compliance.

Industry Developments and Key Companies

The hepatitis B vaccine market is highly competitive, with leading pharmaceutical companies focusing on innovation, partnerships, and expansion of production capacity.

Key companies include:

Sanofi, which continues to expand vaccine manufacturing infrastructure globally and invest heavily in advanced production technologies.
GlaxoSmithKline plc, actively involved in hepatitis vaccine distribution and global immunization programs.
Merck & Co., Inc., contributing to combination vaccine development and global supply.
Dynavax Technologies, known for its recombinant hepatitis B vaccine HEPLISAV-B.
VBI Vaccines Inc., focusing on innovative multi-antigen hepatitis B vaccines like PreHevbrio.
Gilead Sciences, Inc., engaged in therapeutic research and combination treatment strategies.
Chinese manufacturers such as SINOVAC and other biotech firms are expanding production capacity to meet rising domestic and global demand.

Market Segmentation Trends

By type, the combination vaccine segment dominates the market, accounting for 61.18% share in 2026, due to improved immunogenicity, cost-effectiveness, and broader disease protection. Single-antigen vaccines also maintain strong demand, especially in pediatric immunization programs.

By distribution channel, hospitals and retail pharmacies hold the largest share at 64.69% in 2026, as newborn vaccination is commonly administered in healthcare facilities. Government suppliers also play a crucial role, projected to hold around 65% share, driven by national immunization programs and global health initiatives.

Conclusion

Between 2025 and 2034, the hepatitis B vaccine market is expected to grow steadily from USD 9.34 billion to USD 15.54 billion, driven by rising global infection rates, strong immunization policies, and continuous innovation in vaccine technologies. With expanding government support and increasing adoption of combination vaccines, the market presents significant long-term growth opportunities for pharmaceutical companies worldwide.

Segmentation

By Type

Single Antigen
Combination

By Distribution Channel

Hospitals
Government Suppliers
Others

By Region

North America (By Type, Distribution Channel, and Country)
- U.S. (By Type)
- Canada (By Type)
Europe (By Type, Distribution Channel, and Country)
- Germany (By Type)
- France (By Type)
- U.K. (By Type)
- Spain (By Type)
- Italy (By Type)
- Rest of Europe (By Type)
Asia Pacific (By Type, Distribution Channel, and Country)
- China (By Type)
- India (By Type)
- Japan (By Type)
- Australia (By Type)
- Southeast Asia (By Type)
- Rest of Asia Pacific (By Type)
Rest of the World (By Type, Distribution Channel, and Country)

Table of Content

1. Introduction

1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends

4. Key Insights

4.1. Prevalence of Hepatitis B, By Key Countries 2025/2025
4.2. Pipeline Analysis, Key Players
4.3. Key Industry Developments, Mergers, Acquisitions, New Product Launches, Etc.
4.4. Impact of COVID-19 on the Market

5. Global Hepatitis B Vaccine Market Analysis, Insights and Forecast, 2021-2034

5.1. Market Analysis, Insights and Forecast - By Type
- 5.1.1. Single Antigen
- 5.1.2. Combination
5.2. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.2.1. Hospitals & Clinics
- 5.2.2. Government Suppliers
- 5.2.3. Others
5.3. Market Analysis, Insights and Forecast - By Region
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. Asia Pacific
- 5.3.4. Rest of the World

6. North America Hepatitis B Vaccine Market Analysis, Insights and Forecast, 2021-2034

6.1. Market Analysis, Insights and Forecast - By Type
- 6.1.1. Single Antigen
- 6.1.2. Combination
6.2. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.2.1. Hospitals & Clinics
- 6.2.2. Government Suppliers
- 6.2.3. Others
6.3. Market Analysis, Insights and Forecast - By Country
- 6.3.1. U.S.
  - 6.3.1.1. By Type
- 6.3.2. Canada
  - 6.3.2.1. By Type

7. Europe Hepatitis B Vaccine Market Analysis, Insights and Forecast, 2021-2034

7.1. Market Analysis, Insights and Forecast - By Type
- 7.1.1. Single Antigen
- 7.1.2. Combination
7.2. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.2.1. Hospitals & Clinics
- 7.2.2. Government Suppliers
- 7.2.3. Others
7.3. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 7.3.1. Germany
  - 7.3.1.1. By Type
- 7.3.2. France
  - 7.3.2.1. By Type
- 7.3.3. U.K
  - 7.3.3.1. By Type
- 7.3.4. Spain
  - 7.3.4.1. By Type
- 7.3.5. Italy
  - 7.3.5.1. By Type
- 7.3.6. Rest of Europe
  - 7.3.6.1. By Type

8. Asia Pacific Hepatitis B Vaccine Market Analysis, Insights and Forecast, 2021-2034

8.1. Market Analysis, Insights and Forecast - By Type
- 8.1.1. Single Antigen
- 8.1.2. Combination
8.2. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.2.1. Hospitals & Clinics
- 8.2.2. Government Suppliers
- 8.2.3. Others
8.3. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 8.3.1. China
  - 8.3.1.1. By Type
- 8.3.2. India
  - 8.3.2.1. By Type
- 8.3.3. Southeast Asia
  - 8.3.3.1. By Type
- 8.3.4. Japan
  - 8.3.4.1. By Type
- 8.3.5. Australia
  - 8.3.5.1. By Type
- 8.3.6. Rest of Asia Pacific
  - 8.3.6.1. By Type

9. Rest of the World Hepatitis B Vaccine Market Analysis, Insights and Forecast, 2021-2034

9.1. Market Analysis, Insights and Forecast - By Type
- 9.1.1. Single Antigen
- 9.1.2. Combination
9.2. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.2.1. Hospitals & Clinics
- 9.2.2. Government Suppliers
- 9.2.3. Others

10. Competitive Analysis

10.1. Global Market Share Analysis (2025)
10.2. Company Profiles
- 10.2.1. GSK plc
  - 10.2.1.1. Overview
  - 10.2.1.2. Products & Services
  - 10.2.1.3. SWOT Analysis
  - 10.2.1.4. Recent Developments
  - 10.2.1.5. Strategies
  - 10.2.1.6. Financials (Based on Availability)
- 10.2.2. DYNAVAX TECHNOLOGIES
  - 10.2.2.1. Overview
  - 10.2.2.2. Products & Services
  - 10.2.2.3. SWOT Analysis
  - 10.2.2.4. Recent Developments
  - 10.2.2.5. Strategies
  - 10.2.2.6. Financials (Based on Availability)
- 10.2.3. VBI Vaccines Inc.
  - 10.2.3.1. Overview
  - 10.2.3.2. Products & Services
  - 10.2.3.3. SWOT Analysis
  - 10.2.3.4. Recent Developments
  - 10.2.3.5. Strategies
  - 10.2.3.6. Financials (Based on Availability)
- 10.2.4. Sanofi
  - 10.2.4.1. Overview
  - 10.2.4.2. Products & Services
  - 10.2.4.3. SWOT Analysis
  - 10.2.4.4. Recent Developments
  - 10.2.4.5. Strategies
  - 10.2.4.6. Financials (Based on Availability)
- 10.2.5. Merck & Co., Inc.
  - 10.2.5.1. Overview
  - 10.2.5.2. Products & Services
  - 10.2.5.3. SWOT Analysis
  - 10.2.5.4. Recent Developments
  - 10.2.5.5. Strategies
  - 10.2.5.6. Financials (Based on Availability)
- 10.2.6. Beijing Minhai Biological Technology Co., Ltd.
  - 10.2.6.1. Overview
  - 10.2.6.2. Products & Services
  - 10.2.6.3. SWOT Analysis
  - 10.2.6.4. Recent Developments
  - 10.2.6.5. Strategies
  - 10.2.6.6. Financials (Based on Availability)
- 10.2.7. Gilead Sciences, Inc.
  - 10.2.7.1. Overview
  - 10.2.7.2. Products & Services
  - 10.2.7.3. SWOT Analysis
  - 10.2.7.4. Recent Developments
  - 10.2.7.5. Strategies
  - 10.2.7.6. Financials (Based on Availability)
- 10.2.8. Beijing Tiantan Biological Products Co., Ltd.
  - 10.2.8.1. Overview
  - 10.2.8.2. Products & Services
  - 10.2.8.3. SWOT Analysis
  - 10.2.8.4. Recent Developments
  - 10.2.8.5. Strategies
  - 10.2.8.6. Financials (Based on Availability)
- 10.2.9. Amy Vaccine Co., Ltd.
  - 10.2.9.1. Overview
  - 10.2.9.2. Products & Services
  - 10.2.9.3. SWOT Analysis
  - 10.2.9.4. Recent Developments
  - 10.2.9.5. Strategies
  - 10.2.9.6. Financials (Based on Availability)
- 10.2.10. Biokangtai
  - 10.2.10.1. Overview
  - 10.2.10.2. Products & Services
  - 10.2.10.3. SWOT Analysis
  - 10.2.10.4. Recent Developments
  - 10.2.10.5. Strategies
  - 10.2.10.6. Financials (Based on Availability)

簡介目錄圖表

List of Tables

Table 01: Global Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
Table 02: Global Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
Table 03: Global Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Region, 2021-2034
Table 04: North America Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
Table 05: North America Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
Table 06: North America Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Country, 2021-2034
Table 07: U.S. Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
Table 08: Canada Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
Table 09: Europe Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
Table 10: Europe Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
Table 11: Europe Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Country/Sub-region, 2021-2034
Table 12: Germany Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
Table 13: France Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
Table 14: U.K. Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
Table 15: Spain Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
Table 16: Italy Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
Table 17: Rest of Europe Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
Table 18: Asia Pacific Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
Table 19: Asia Pacific Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
Table 20: Asia Pacific Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Country/Sub-region, 2021-2034
Table 21: China Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
Table 22: India Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
Table 23: Southeast Asia Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
Table 24: Japan Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
Table 25: Australia Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
Table 26: Rest of Asia Pacific Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
Table 27: Rest of the World Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Type, 2021-2034
Table 28: Rest of the World Hepatitis B Vaccine Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034

List of Figures

Figure 01: Global Hepatitis B Vaccine Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
Figure 02: Global Hepatitis B Vaccine Market Value Share (%), By Type, 2025 & 2034
Figure 03: Global Hepatitis B Vaccine Market Value Share (%), By Distribution Channel, 2025 & 2034
Figure 04: Global Hepatitis B Vaccine Market Value Share (%), By Region, 2025 & 2034
Figure 05: North America Hepatitis B Vaccine Market Value (USD billion), by Type, 2025 & 2034
Figure 06: North America Hepatitis B Vaccine Market Value Share (%), by Type, 2025
Figure 07: North America Hepatitis B Vaccine Market Value (USD billion), by Distribution Channel, 2025 & 2034
Figure 08: North America Hepatitis B Vaccine Market Value Share (%), by Distribution Channel, 2025
Figure 09: North America Hepatitis B Vaccine Market Value (USD billion), by Country, 2025 & 2034
Figure 10: North America Hepatitis B Vaccine Market Value Share (%), by Country, 2025
Figure 11: Europe Hepatitis B Vaccine Market Value (USD billion), by Type, 2025 & 2034
Figure 12: Europe Hepatitis B Vaccine Market Value Share (%), by Type, 2025
Figure 13: Europe Hepatitis B Vaccine Market Value (USD billion), by Distribution Channel, 2025 & 2034
Figure 14: Europe Hepatitis B Vaccine Market Value Share (%), by Distribution Channel, 2025
Figure 15: Europe Hepatitis B Vaccine Market Value (USD billion), by Country/Sub-region, 2025 & 2034
Figure 16: Europe Hepatitis B Vaccine Market Value Share (%), by Country/Sub-region, 2025
Figure 17: Asia Pacific Hepatitis B Vaccine Market Value (USD billion), by Type, 2025 & 2034
Figure 18: Asia Pacific Hepatitis B Vaccine Market Value Share (%), by Type, 2025
Figure 19: Asia Pacific Hepatitis B Vaccine Market Value (USD billion), by Distribution Channel, 2025 & 2034
Figure 20: Asia Pacific Hepatitis B Vaccine Market Value Share (%), by Distribution Channel, 2025
Figure 21: Asia Pacific Hepatitis B Vaccine Market Value (USD billion), by Country/Sub-region, 2025 & 2034
Figure 22: Asia Pacific Hepatitis B Vaccine Market Value Share (%), by Country/Sub-region, 2025
Figure 23: Rest of the World Hepatitis B Vaccine Market Value (USD billion), by Type, 2025 & 2034
Figure 24: Rest of the World Hepatitis B Vaccine Market Value Share (%), by Type, 2025
Figure 25: Rest of the World Hepatitis B Vaccine Market Value (USD billion), by Distribution Channel, 2025 & 2034
Figure 26: Rest of the World Hepatitis B Vaccine Market Value Share (%), by Distribution Channel, 2025
Figure 27: Global Hepatitis B Vaccines Market Share Analysis (%), By Company, 2025